Levitsky D A, Troiano R
Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853.
Am J Clin Nutr. 1992 Jan;55(1 Suppl):167S-172S. doi: 10.1093/ajcn/55.1.167s.
The chronic ingestion of fenfluramine results in a sustained depression in body weight despite the return of ad libitum food intake to normal levels. This chronic suppression of body weight is immediately reversed after discontinuation of the drug treatment. Such a phenomenon indicates that the drug must increase metabolic rate. However, studies in both humans and animals have failed to demonstrate an increase in metabolic rate after the administration of the drug. Instead, fenfluramine appears to potentiate the expenditure of energy whenever increases in energy expenditure occur. Fenfluramine potentiates the thermic effect of food (TEF) both in animals as well as in humans. Moreover, the energy cost of locomotor behavior also appears to be potentiated by this drug. Most importantly from a therapeutic perspective, unlike the anorectic effect of fenfluramine, tolerance does not appear to develop to its ability to potentiate energy expenditure.
长期摄入芬氟拉明会导致体重持续下降，尽管随意进食量已恢复到正常水平。这种体重的长期抑制在停止药物治疗后会立即逆转。这种现象表明该药物必定会提高代谢率。然而，对人类和动物的研究均未能证明给药后代谢率有所提高。相反，每当能量消耗增加时，芬氟拉明似乎会增强能量消耗。芬氟拉明在动物和人类中均能增强食物的热效应（TEF）。此外，该药物似乎还能增强运动行为的能量消耗。从治疗角度来看，最重要的是，与芬氟拉明的厌食作用不同，其增强能量消耗的能力似乎不会产生耐受性。
